Cassava Sciences, Inc. (SAVA) |
|
26.34 -0.41 (-1.53%)
|
03-17 16:00 |
|
Open: |
26.7 |
Pre. Close: |
26.75 |
|
High:
|
26.7 |
Low:
|
25.69 |
|
Volume:
|
789,556 |
Market Cap:
|
1,099(M) |
|
|
|
Technical analysis |
as of: 2023-03-20 8:49:13 AM |
|
Overall:
|
 |
| Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
| Target: |
Six months: 31.41  One year: 33.46 |
| Support: |
Support1: 24.05 Support2: 20.01 |
| Resistance: |
Resistance1: 26.89 Resistance2: 28.64 |
| Pivot: |
25.55  |
| Moving Average: |
MA(5): 26.15 MA(20): 25.55
MA(100): 31.77 MA(250): 29.39 |
| MACD: |
MACD(12,26): -0.6 Signal(9): -1 |
| Stochastic oscillator: |
%K(14,3): 70.9 %D(3): 64.8 |
| RSI: |
RSI(14): 48.6 |
| 52-week: |
High: 51.59 Low: 13.84 |
| Average Vol(K): |
3-Month: 1,359 (K) 10-Days: 906 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ SAVA ] has closed below upper band by 21.4%. Bollinger Bands are 70.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 12 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
26.72 - 26.86 |
26.86 - 26.94 |
|
Low:
|
25.37 - 25.55 |
25.55 - 25.66 |
|
Close:
|
26.08 - 26.35 |
26.35 - 26.53 |
|
Company Description |
|
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas. |
Headline News |
Thu, 16 Mar 2023
Cassava Sciences (SAVA): Can Pharma Company Boost Own ... - The Coin Republic
Thu, 09 Mar 2023
Why Cassava Sciences Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket - Asana (NYSE: - Benzinga
Thu, 09 Mar 2023
Cassava Sciences Surges 12% After Hours as Board Member ... - Nasdaq
Wed, 08 Mar 2023
Tesla, Apple, Cassava, MongoDB, Asana: Top Trending Stocks - Asana (NYSE:ASAN), Apple (NASDAQ:AAPL), Tesl - Benzinga
Wed, 08 Mar 2023
Why Cassava Sciences Stock Is Surging After Hours - Cassava Sciences (NASDAQ:SAVA) - Benzinga
Mon, 06 Mar 2023
Is Cassava Sciences Inc (SAVA) a Leader in the Biotechnology Industry? - InvestorsObserver
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
42 (M) |
| Shares Float |
38 (M) |
|
% Held by Insiders
|
5.4 (%) |
|
% Held by Institutions
|
26.8 (%) |
|
Shares Short
|
10,320 (K) |
|
Shares Short P.Month
|
8,800 (K) |
Stock Financials |
|
EPS
|
-0.31 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
7.03 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-19.1 |
|
Return on Equity (ttm)
|
-30.6 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
-0.6 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-1.74 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-64 (M) |
|
Levered Free Cash Flow
|
-42 (M) |
Stock Valuations |
|
PE Ratio
|
-87.8 |
|
PEG Ratio
|
-0.2 |
|
Price to Book value
|
3.74 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-17.14 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
2017-05-09 |
|
Ex-Dividend Date
|
2012-12-12 |
|
Your Ad Here
|
|
